This trial will test whether the drug dupilumab can help improve symptoms in people with allergic contact dermatitis.
1 Primary · 7 Secondary · Reporting Duration: week 0, week0+72-120 hours, week 12 and week 12+72-120 hours
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Dupilumab · No Placebo Group · Phase 4
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: